ACK1/TNK2 tyrosine kinase: Molecular signaling and evolving role in cancers

Oncogene

Volumn 34, Issue 32, 2015, Pages 4162-4167

  Mahajan, K ^a,b   Mahajan, N P ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CDC42 ASSOCIATED KINASE 1; ANDROGEN RECEPTOR; BOSUTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HISTONE DEMETHYLASE; PROTEIN TYROSINE KINASE; RUXOLITINIB; TAMOXIFEN; TRANSCRIPTION FACTOR HOXA10; UNCLASSIFIED DRUG; PROTEIN BINDING; TNK2 PROTEIN, HUMAN;

BREAST CANCER; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC NEUTROPHILIC LEUKEMIA; ENZYME ACTIVATION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENOTOXICITY; HUMAN; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION REGULATION; UPREGULATION; BREAST TUMOR; FEMALE; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

BREAST NEOPLASMS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84938974494     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.350     Document Type: Review

References (53)

1. Mahajan K, Mahajan NP. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol 2010; 224: 327-333.
2. Mahajan K, Mahajan NP. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol 2012; 227: 3178-3184.
3. Manser E, Leung T, Salihuddin H, Tan L, Lim L. A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993; 363: 364-367.
4. Mahajan NP, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 2005; 65: 10514-10523.
5. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007; 104: 8438-8443.
6. Yokoyama N, Miller WT. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck. J Biol Chem 2003; 278: 47713-47723.
7. Gajiwala KS, Maegley K, Ferre R, He YA, Yu X. Ack1: activation and regulation by allostery. PLoS ONE 2013; 8: e53994.
8. Prieto-Echague V, Miller WT. Regulation of ack-family nonreceptor tyrosine kinases. J Signal Transduct 2011; 2011: 742372.
9. Prieto-Echague V, Gucwa A, Craddock BP, Brown DA, Miller WT. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. J Biol Chem 2010; 285: 10605-10615.
10. Lin Q, Wang J, Childress C, Yang W. The activation mechanism of ACK1 (activated Cdc42-associated tyrosine kinase 1). Biochem J 2012; 445: 255-264.
11. Prieto-Echague V, Gucwa A, Brown DA, Miller WT. Regulation of Ack1 localization and activity by the amino-terminal SAM domain. BMC Biochem 2010; 11: 42.
12. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One 2010; 5: e9646.
13. Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 2010; 70: 1274-1285.
14. Shen F, Lin Q, Gu Y, Childress C, Yang W. Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol Biol Cell 2007; 18: 732-742.
15. Chan W, Tian R, Lee YF, Sit ST, Lim L, Manser E. Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2. J Biol Chem 2009; 284: 8185-8194.
16. Jones S, Cunningham DL, Rappoport JZ, Heath JK. The non-receptor tyrosine kinase Ack1 regulates the fate of activated EGFR by inducing trafficking to the p62/NBR1 pre-autophagosome. J Cell Sci 2014; 127: 994-1006.
17. Buchwald M, Pietschmann K, Brand P, Gunther A, Mahajan NP, Heinzel T et al. SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation. Oncogene 2012; 32: 4913-4920.
18. Kramer OH, Stauber RH, Bug G, Hartkamp J, Knauer SK. SIAH proteins: critical roles in leukemogenesis. Leukemia 2013; 27: 792-802.
19. Urena JM, La Torre A, Martinez A, Lowenstein E, Franco N, Winsky-Sommerer R et al. Expression, synaptic localization, and developmental regulation of Ack1/ Pyk1, a cytoplasmic tyrosine kinase highly expressed in the developing and adult brain. J Comp Neurol 2005; 490: 119-132.
20. La Torre A, del Rio JA, Soriano E, Urena JM. Expression pattern of ACK1 tyrosine kinase during brain development in the mouse. Gene Expr Patterns 2006; 6: 886-892.
21. La Torre A, del Mar Masdeu M, Cotrufo T, Moubarak RS, del Rio JA, Comella JX et al. A role for the tyrosine kinase ACK1 in neurotrophin signaling and neuronal extension and branching. Cell Death Dis 2013; 4: e602.
22. Hitomi Y, Heinzen EL, Donatello S, Dahl HH, Damiano JA, McMahon JM et al. Mutations in TNK2 in severe autosomal recessive infantile onset epilepsy. Ann Neurol 2013; 74: 496-501.
23. Galisteo ML, Yang Y, Urena J, Schlessinger J. Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci USA 2006; 103: 9796-9801.
24. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci USA 2005; 102: 15901-15906.
25. Mahajan K, Mahajan NP. ACK1/TNK2 tyrosine kinase:An emerging target for cancer therapeutics. AACR Educ Book 2014; 2014: 6.
26. Shinmura K, Kiyose S, Nagura K, Igarashi H, Inoue Y, Nakamura S et al. TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer. J Surg Oncol 2013; 109: 189-197.
27. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
28. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-7425.
29. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120: 2479-2487.
30. Mahajan K, Coppola D, Chen YA, Zhu W, Lawrence HR, Lawrence NJ et al. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol 2012; 180: 1386-1393.
31. Schoenherr JA, Drennan JM, Martinez JS, Chikka MR, Hall MC, Chang HC et al. Drosophila activated Cdc42 kinase has an anti-apoptotic function. PLoS Genet 2012; 8: e1002725.
32. Burnstein KL. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 2005; 95: 657-669.
33. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
34. Lupien M, Brown M. Cistromics of hormone-dependent cancer. Endocr Relat Cancer 2009; 16: 381-389.
35. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev 2001; 1: 34-45.
36. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 2005; 95: 1320-1326.
37. Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW et al. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem 2012; 287: 22112-22122.
38. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28: 1379-1386.
39. Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol 2013; 75: 225-240.
40. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007; 7: 713-722.
41. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
42. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662.
43. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30.
44. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53: 25-71.
45. Mahajan K, Lawrence HR, Lawrence NJ, Mahajan NP. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem 2014; 289: 28179-28191.
46. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115.
47. Matsumoto J, Kaneda M, Tada M, Hamada J, Okushiba S, Kondo S et al. Differential mechanisms of constitutive Akt/PKB activation and its influence on gene expression in pancreatic cancer cells. Jpn J Cancer Res 2002; 93: 1317-1326.
48. Sakurada A, Suzuki A, Sato M, Yamakawa H, Orikasa K, Uyeno S et al. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 1997; 88: 1025-1028.
49. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368: 1781-1790.
50. Mahajan K, Mahajan NP. ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. Cancer Lett 2013; 338: 185-192.
51. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits sitespecific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 2010; 29: 3208-3216.
52. Tan DS, Haaland B, Gan JM, Tham SC, Sinha I, Tan EH et al. Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer. Mol Cancer 2014; 13: 13.
53. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL et al. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR. Bioorg Med Chem Lett 2007; 17: 2305-2309.